Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Telotristat etiprate (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms TELE-ABC
  • Sponsors Lexicon Pharmaceuticals; TerSera Therapeutics

    • Most Recent Events

    • 20 Jan 2024 Primary endpoint (Progression free survival (PFS) rate according to RECIST 1.1. at Month 6) has not been met, according to results presented at the 2024 Gastrointestinal Cancers Symposium
    • 20 Jan 2024 Results assessing the safety and efficacy of adding TE to GC chemotherapy in pts with advanced Biliary Tract Cancer. presented at the 2024 Gastrointestinal Cancers Symposium
    • 25 Jan 2023 This study protocol has been amended as primary end point (Incidence of treatment emergent adverse events) has been removed and primary endpoint (Overall Survival) has been added. Hence, the focus has been shifted to Tu only.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top